Mytoxid

Mytoxid Uses, Dosage, Side Effects, Food Interaction and all others data.

Mytoxid is an antineoplastic antibiotic which is enzymatically reduced to its active metabolite within susceptible cells. The active metabolite appears to cause cross-linking of DNA (primarily with guanine and cytosine pairs). It is also active against gm+ve bacteria and some viruses.

Mytoxid is one of the older chemotherapy drugs, which has been around and in use for decades. It is an antibiotic which has been shown to have antitumor activity. Mytoxid selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mytoxid has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.

Mytoxid
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Mytoxid
Availability	Prescription only
Generic	Mitomycin
Mitomycin Other Names	Ametycine, Mitamycin, Mitocin-C, Mitomycin, Mitomycin C
Related Drugs	Keytruda, capecitabine, pembrolizumab, fluorouracil, doxorubicin, cisplatin, Opdivo, nivolumab, gemcitabine, everolimus
Type
Formula	C₁₅H₁₈N₄O₅
Weight	Average: 334.3272 Monoisotopic: 334.127719706
Groups	Approved
Therapeutic Class	Cytotoxic Chemotherapy
Manufacturer
Available Country	Philippines
Last Updated:	September 19, 2023 at 7:00 am

Uses

This is used for Diabetic foot infections; Chronic lymphatic leukaemia; Chronic myelogenous leukaemia; Gastric, Colorectal, Lung, Pancreatic, Cervix, Endometrium, Breast, Bladder, Head & neck carcinoma.

Mytoxid is also used to associated treatment for these conditions: Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, Breast Cancer, Cancer, Anal, Cancer, Bladder, Cervical Cancers, Head and Neck Carcinoma, Mesothelioma, Non-Small Cell Lung Carcinoma (NSCLC), Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)

How Mytoxid works

Mytoxid is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mytoxid is cell cycle phase-nonspecific.

Dosage

Mytoxid dosage

Solid tumours Suggested regimen: Initial: 10-20 mg/m2; may repeat 6-8 wkly depending on blood count. Do not repeat if leucocyte and platelet counts are below acceptable levels. Do not re-administer if the nadir of the leucocyte count is <2,000 cells/mm3

Intravesical Superficial bladder tumours: Instill 10-40 mg 1 -3 times/wk for a total of 20 doses

Prevention of recurrent bladder tumours: Instill 20 mg 2 wkly or 40 mg 1-3-mthly.

Intravenous: Reconstitute by adding 10, 40 or 80 mL of sterile water for inj to a vial labeled as containing 5, 20, or 40 mg respectively, to provide a soln containing approx 0.5 mg/mL. The vial should be shaken to enhance dissolution. If the powd for inj does not dissolve immediately, allow the vial to stand at room temp until complete dissolution occurs.

Side Effects

Hemolytic uremic syndrome (<15%), Myelosuppression (64%), Nausea/ vomiting (14%), Fever (14%), Stomatitis (4%), Increased serum creatinine (2%), Mucous membrane toxicity (4%) , Fatigue, Pulmonary toxicity, Dyspnea, Cystitis, Interstitial fibrosis, Nephrotoxicity, Amenorrhea, Alopecia, Myelosuppression, haemolytic-uraemic syndrome.

Toxicity

Oral, mouse: LD₅₀ = 23 mg/kg; Oral, rat: LD₅₀ = 30 mg/kg. Symptoms of overdose include nausea and vomiting.

Precaution

Repeated haematologic studies are necessary during treatment and for at least 7 wk after discontinuation of the drug. Discontinue use when the leucocyte count decreases to <4000/mm3 or the platelet count decreases to <150,000/mm3 or if a progressive decline in either occurs. Monitor patient for signs of renal or pulmonary toxicity.

Interaction

Increased incidence of cardiotoxicity with doxorubicin.

Food Interaction

No interactions found.

Mytoxid Drug Interaction

Moderate: doxorubicinMinor: ciprofloxacin, levofloxacinUnknown: charcoal, amoxicillin, RHO Immunoglobulin , lorazepam, amoxicillin / clavulanate, citalopram, sulfamethoxazole / trimethoprim, glucose, diltiazem, iodine / potassium iodide, pregabalin, metoprolol, metoprolol, mirabegron, acetaminophen, cholecalciferol, ondansetron

Mytoxid Disease Interaction

Major: infections, bleeding disorders, myelosuppression, renal dysfunction

Elimination Route

Erratic.

Half Life

8-48 min

Elimination Route

Approximately 10% of a dose of mitomycin is excreted unchanged in the urine.

Pregnancy & Breastfeeding use

Pregnancy category- D

Contraindication

Hypersensitivity. Patient with platelet counts <100,000/mm3, leukocyte counts <4,000/mm3 or serum creatinine concentration >1.7 mg/dL. Patient with substantial prolongation of prothrombin time or bleeding time, coagulation disorders, increased bleeding tendency. Pregnancy and lactation.